OTCMKTS:KALTF Claritas Pharmaceuticals (KALTF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChart About Claritas Pharmaceuticals Stock (OTCMKTS:KALTF) Get KALTF alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume9,705 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Claritas Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing therapies for serious and potentially life-threatening diseases. The company’s work has centered on novel drug candidates intended to address unmet needs in areas including infectious disease, inflammation and respiratory conditions. Claritas’ lead development program has involved R-107, an oral, controlled-release nitric oxide donor. The candidate has been evaluated for its potential use in COVID-19 and related respiratory complications, although the company’s product candidates remain subject to clinical testing and regulatory review and are not necessarily approved for commercial use. The company was formerly known as Kalytera Therapeutics Inc. and adopted the Claritas Pharmaceuticals name as it repositioned its business toward pharmaceutical drug development. Publicly available information about its current operations, geographic reach and leadership is limited.AI Generated. May Contain Errors. Read More Receive KALTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALTF Stock News HeadlinesClaritas Rx Appoints Biopharma Commercial Leader Jonathan Witt to Board of DirectorsOctober 13, 2026 | tmcnet.comClaritas Rx Access Analytics Delivers Real-Time Visibility Into Biopharma Brand PerformanceSeptember 9, 2025 | tmcnet.comNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.October 29 at 1:00 AM | Porter & Company (Ad)Charlottesville, VirginiaMay 5, 2024 | forbes.comDPHAY - Dechra Pharmaceuticals PLCJuly 6, 2023 | finance.yahoo.comAnimal Health Active Pharmaceutical Ingredients Market Research Insights with Upcoming Trends Segmentation, Opportunities and Forecast to 2030June 22, 2023 | marketwatch.comACXP - Acurx Pharmaceuticals, Inc.June 21, 2023 | finance.yahoo.comPharmaceutical Lecithin Market Size, Growth, Outlook, Share, Segmentation Analysis, Revenue And Forecast 2031April 27, 2023 | marketwatch.comSee More Headlines KALTF Stock Analysis - Frequently Asked Questions How were Claritas Pharmaceuticals' earnings last quarter? Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF) announced its quarterly earnings results on Friday, November, 29th. The company reported ($0.40) earnings per share (EPS) for the quarter. When did Claritas Pharmaceuticals' stock split? Shares of Claritas Pharmaceuticals reverse split on Friday, July 23rd 2021.The 1-20 reverse split was announced on Friday, July 23rd 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 23rd 2021. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Claritas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Claritas Pharmaceuticals investors own include Alnylam Pharmaceuticals (ALNY), Advanced Micro Devices (AMD), Skyworks Solutions (SWKS), Bank of America (BAC), Nokia (NOK), Aurora Cannabis (ACBFF) and Cannabis Wheaton Income (CBWTF). Company Calendar Last Earnings11/29/2013Today10/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:KALTF Previous SymbolOTCMKTS:QUEZF CIKN/A Webkalytera.co Phone(888) 861-2008FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:KALTF) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Claritas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Claritas Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
